India’s obesity-drug price war is no longer a future story. It is happening now. Reuters reported on March 31 that Novo Nordisk cut prices for Ozempic and Wegovy in India again, after the patent on semaglutide expired on March 20, 2026, opening the market to cheaper local generics. That matters because India is one of the few big markets where branded global drugs, fast-moving local generics, and price-sensitive patients are colliding at full speed.
What exactly changed
Reuters reported that Novo reduced the lowest 0.25 mg dose of both Ozempic and Wegovy to ₹1,415, down from ₹2,200 and ₹2,712 respectively. It said the average price cut was 23.8% for Ozempic and 27% for Wegovy, while some headline cuts were even steeper, reaching 36% and 48% on certain doses. Higher-dose products also became cheaper, with the 1 mg weekly shot now priced at ₹2,275, after reductions of up to 34.2%.
Why Novo had to cut again
The blunt answer is competition. Reuters reported that Indian drugmakers including Dr. Reddy’s, Zydus, and Sun Pharma are entering the semaglutide market, and some generics are priced up to 70% lower than Novo’s original products. Earlier Reuters reporting also said Dr. Reddy’s believed discounts of 50% to 60% versus branded Wegovy were feasible. That is brutal pressure in a market where affordability decides volume.
Why India matters so much
India is not just another launch market. Reuters reported in December 2025 that India has the world’s second-largest population of people with type 2 diabetes, and Novo launched Ozempic there partly to tap a market it viewed as potentially enormous. But India is also unusually price-sensitive. That means premium pricing can work only for a narrow slice of patients before generics start eating away at market share.
This is not only about obesity
A lot of lazy coverage frames these drugs as cosmetic weight-loss products. That is wrong. Reuters noted that Ozempic is a diabetes drug that is also used off-label for weight loss, while Novo said its India pricing move reflected patient and doctor feedback and highlighted the medicines’ cardiovascular benefits. So this pricing fight affects both the obesity-treatment market and diabetes care economics.
The market pressure points
| Issue | Current reported detail | Why it matters |
|---|---|---|
| Patent expiry | Semaglutide patent expired on March 20, 2026 | Opened the door to local generic competition |
| Lowest new price | 0.25 mg dose cut to ₹1,415 | Shows how aggressively Novo is defending share |
| Average Ozempic cut | 23.8% | Significant branded-price reset |
| Average Wegovy cut | 27% | Confirms the obesity segment is under pressure |
| Generic discount potential | Up to 50%–70% lower | Makes further price pressure likely |
| Key local challengers | Dr. Reddy’s, Zydus, Sun Pharma | Strong domestic competition is already forming |
This table shows the real point: the market is moving from premium-brand control to active price competition, and that shift usually does not reverse easily.
Why this could reshape the whole category
Once generics arrive at scale, two things usually happen. First, patient access expands because more people can afford treatment. Second, branded companies lose pricing power fast unless they can defend themselves with trust, supply reliability, doctor preference, or patient-support programs. Reuters’ reporting suggests Novo is trying to do exactly that by cutting prices before generics fully dominate. That is a defensive move, not a sign of comfort. This interpretation is based on Reuters’ reporting about repeated price cuts and rising generic threats.
Eli Lilly is part of the pressure too
This is not only Novo versus Indian generics. Reuters also reported that Eli Lilly’s Mounjaro gained traction quickly in India and became a top seller after launch. That means Novo is being squeezed from two directions: cheaper local copies below it and a powerful global rival beside it. Markets like that get ugly fast.
What readers should watch next
The useful signals are straightforward:
- whether more Indian generics win approvals quickly
- how deep the next round of price cuts goes
- whether doctors still favor branded Ozempic and Wegovy
- whether Lilly responds more aggressively in pricing or distribution
Conclusion
India’s obesity drug price war is real because the old pricing structure has already cracked. Novo Nordisk is cutting Ozempic and Wegovy again, semaglutide generics are arriving, and local manufacturers look ready to undercut branded products hard. That is good news for access, but bad news for anyone pretending premium pricing can stay untouched in India once copycats arrive. The market is not stabilizing. It is being repriced in real time.
FAQs
Why did Novo Nordisk cut Ozempic and Wegovy prices in India again?
Because semaglutide’s patent expired in India on March 20, 2026, and Reuters reported that cheaper local generics are now entering the market.
How much were prices cut?
Reuters reported the lowest 0.25 mg dose dropped to ₹1,415, with average cuts of 23.8% for Ozempic and 27% for Wegovy.
Which Indian companies are competing in semaglutide?
Reuters named Dr. Reddy’s, Zydus, and Sun Pharma among the companies moving into the category.
Are these drugs only for weight loss?
No. Ozempic is primarily a diabetes drug, though it is also used off-label for weight loss, and Novo has highlighted additional cardiovascular benefits.